Skip to main content

Table 3 Characteristics of clinical trials

From: Mesenchymal stem cells for the treatment of ulcerative colitis: a systematic review and meta-analysis of experimental and clinical studies

First author Year Location Type of study Number of MSC group Number of control group Male/female Age Type and source of MSCs Way of MSCs administrated Outcomes Adverse events MINORS
Knyazev, O. 2017 Russia Meeting abstract 26 N/A N/A 20–62 (mean 28) BM-MSCs Submucosal injection by colonoscopy One-year healing rate 23/26 N/A 9
Yang, Bo. 2015 China Full text 7 10 13/4 37–62 BM-MSCs Submucosal injection by colonoscopy 14-month healing rate 7/7, 3/10 N/A 16
Lazebnik, L. 2011 Russian Meeting abstract 44 N/A N/A N/A BM-MSC N/A One-year healing rate 32/44 N/A 9
Jun Liang 2012 China Letter 3 N/A 1/2 22–44 (mean 29) BM-MSC N/A One-year healing rate 2/3 N/A
Insomnia; low; fever
7
Lazebnik, L. 2010 Russian Meeting abstract 44 N/A N/A N/A BM-MSC Intravenous Infusions Two-year healing rate 34/44 N/A 9
Knyazev, Oleg 2013 Russian Meeting abstract 58 50 N/A 19–64 (mean 36) BM-MSC Intravenous Infusions One-year healing rate 44/58, 17/50 N/A 16
Jian-Xia Hu 2016 China Full text 34 36 21/13 22/14 42.9 ± 23.1 and 43.7 ± 28.7 UC-MSCs Intravenous infusions One-year healing rate 85.3%, 16.7% N/A 22
  1. BM-MSCs bone marrow MSCs, UC-MSCs umbilical cord MSCs, MINORS methodological index for non-randomized studies